{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:29:42Z","timestamp":1792758582589,"version":"4.5.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2019-0655_s_999\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic sclerosis (SSc) and primary biliary cholangitis (PBC) are autoimmune diseases that may occur concomitantly and are both strongly associated with disease-specific autoantibodies. This study investigated the prevalence and fine specificity of PBC-specific serology (PBC-Ab) and associations with the SSc-subtypes and SSc-specific antibodies as well as the association with cholestatic liver enzymes. Furthermore, three different techniques for the detection of PBC-Ab were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2019-0655_s_998\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum of 184 Belgian SSc patients with a known SSc-antibody profile, was analyzed for PBC-Ab (antimitochondrial antibodies [AMA], anti-Gp210, anti-Sp100 and anti-PML) using indirect immunofluorescence (IIF) analysis on human epithelioma-2000 (HEp-2000) cells (ANA-IIF, Immunoconcepts) and liver-kidney-stomach tissue sections (IIF-LKS) (Menarini), and a line immunoblot (LB) (EuroImmun). Alkaline phosphatase\/\u03b3-glutamyl transferase (ALP\/GGT) were evaluated at time of first sampling (t0) and after 3 years of follow-up (t3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2019-0655_s_997\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PBC-Ab were present in 13% of patients and significantly correlated with centromere antibodies (anti-CENP-B), but not correlated with the limited cutaneous SSc subgroup (lcSSc). The most frequent reactivities were AMA (11%, with 9% AMA-M2) and Sp-100 antibodies (5%), showing a major overlap. There was no relevant association between the presence of PBC-Ab and ALP or GGT elevation at t0 nor at t3. Detection of AMA with IIF-LKS is comparable to LB. ANA-IIF screening was less sensitive compared to LB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2019-0655_s_996\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A wide range of PBC-Ab is detectable in SSc in the absence of cholestatic liver enzyme elevations, even after 3 years of follow-up. However, as these antibodies may precede PBC-disease up to 10 years further prospective follow-up of our cohort will be necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2019-0655","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T04:03:18Z","timestamp":1573531398000},"page":"416-423","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of the primary biliary cholangitis-related serologic profile in a large cohort of Belgian systemic sclerosis patients"],"prefix":"10.1515","volume":"58","author":[{"given":"Lisa","family":"Florin","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine , Ghent University Hospital , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaat","family":"Rubben","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Ghent University Hospital , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Vanhaecke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology , Ghent University Hospital , Ghent , Belgium"},{"name":"Department of Internal Medicine , Ghent University , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Devreese","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Ghent University Hospital , Ghent , Belgium"},{"name":"Department of Diagnostic Sciences , Ghent University , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"De Keyser","sequence":"additional","affiliation":[{"name":"Department of Rheumatology , Ghent University Hospital , Ghent , Belgium"},{"name":"Praktijk 10A , Maldegem , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Rheumatology , Ghent University Hospital , Ghent , Belgium"},{"name":"Department of Internal Medicine , Ghent University , Ghent , Belgium"},{"name":"Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC) , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien","family":"Bonroy","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Sciences , Ghent University , Ghent , Belgium"},{"name":"Department of Laboratory Medicine , Ghent University Hospital , Corneel Heymanslaan 10 , 9000 Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"2023033111232997585_j_cclm-2019-0655_ref_001","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202\u20135."},{"key":"2023033111232997585_j_cclm-2019-0655_ref_002","doi-asserted-by":"crossref","unstructured":"Bonroy C, Van Praet J, Smith V, Van Steendam K, Mimori T, Deschepper E, et al. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 2012;379:53\u201360.","DOI":"10.1016\/j.jim.2012.03.001"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_003","doi-asserted-by":"crossref","unstructured":"Hirschfield GM, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M, et al. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145\u201372.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_004","doi-asserted-by":"crossref","unstructured":"Bonroy C, Smith V, Van Steendam K, Van Praet J, Deforce D, Devreese K, et al. The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies. Clin Chem Lab Med 2013;51:2151\u201360.","DOI":"10.1515\/cclm-2013-0211"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_005","doi-asserted-by":"crossref","unstructured":"Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007;19:580\u201391.","DOI":"10.1097\/BOR.0b013e3282e7d8f9"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_006","doi-asserted-by":"crossref","unstructured":"Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399\u2013402.","DOI":"10.1016\/S0140-6736(96)04410-8"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_007","doi-asserted-by":"crossref","unstructured":"Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986;6:1279\u201384.","DOI":"10.1002\/hep.1840060609"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_008","doi-asserted-by":"crossref","unstructured":"Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front Immunol 2015;6:412.","DOI":"10.3389\/fimmu.2015.00412"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_009","doi-asserted-by":"crossref","unstructured":"Yamagiwa S, Kamimura H, Takamura M, Aoyagi Y. Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol 2014;20:2606\u201312.","DOI":"10.3748\/wjg.v20.i10.2606"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_010","doi-asserted-by":"crossref","unstructured":"Rigamonti C, Shand LM, Feudjo M, Bun CC, Black CM, Denton CP, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006;55:388\u201394.","DOI":"10.1136\/gut.2005.075002"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_011","doi-asserted-by":"crossref","unstructured":"Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004;97:397\u2013406.","DOI":"10.1093\/qjmed\/hch078"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_012","doi-asserted-by":"crossref","unstructured":"Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009;36:2250\u20136.","DOI":"10.3899\/jrheum.090340"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_013","doi-asserted-by":"crossref","unstructured":"Imura-Kumada S, Hasegawa M, Matsushita T, Hamaguchi Y, Encabo S, Shums Z, et al. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Mod Rheumatol 2012;22:892\u20138.","DOI":"10.1007\/s10165-012-0607-z"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_014","doi-asserted-by":"crossref","unstructured":"Avouac J, Airo P, Dieude P, Caramaschi P, Tiev K, Diot E, et al. Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients. J Rheumatol 2010;37:608\u201314.","DOI":"10.3899\/jrheum.090815"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_015","doi-asserted-by":"crossref","unstructured":"Mari-Alfonso B, Simeon-Aznar CP, Guill\u00e9n-Del Castillo A, Rubio-Rivas M, Trapiella-Mart\u00ednez L, Todol\u00ed-Parra JA, et al. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: characteristics and survival of patients from the Spanish RESCLE Registry. Semin Arthritis Rheum 2018;47:849\u201357.","DOI":"10.1016\/j.semarthrit.2017.10.004"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_016","doi-asserted-by":"crossref","unstructured":"Mytilinaiou MG, Bogdanos DP. Primary biliary cirrhosis-specific autoantibodies in patients with systemic sclerosis. Dig Liver Dis 2009;41:916.","DOI":"10.1016\/j.dld.2009.05.005"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_017","doi-asserted-by":"crossref","unstructured":"Norman GL, Bialek A, Encabo S, Butkiewicz B, Wiechowska-Kozlowzka A, Brzosko M, et al. Is prevalence of PBC underestimated in patients with systemic sclerosis? Dig Liver Dis 2009;41:762\u20134.","DOI":"10.1016\/j.dld.2009.01.014"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_018","doi-asserted-by":"crossref","unstructured":"Cavazzana I, Ceribelli A, Taraborelli M, Fredi M, Norman G, Tincani A, et al. Primary biliary cirrhosis-related autoantibodies in a large cohort of Italian patients with systemic sclerosis. J Rheumatol 2011;38:2180\u20135.","DOI":"10.3899\/jrheum.110167"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_019","unstructured":"LeRoy EC, Medsger JR. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573\u20136."},{"key":"2023033111232997585_j_cclm-2019-0655_ref_020","doi-asserted-by":"crossref","unstructured":"Vandecasteele E, Drieghe B, Melsens K, Thevissen K, De Pauw M, Deschepper E, et al. Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J 2017;49:1\u20139.","DOI":"10.1183\/13993003.02275-2016"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_021","doi-asserted-by":"crossref","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737\u201347.","DOI":"10.1002\/art.38098"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_022","unstructured":"Clark-Carter D. Encyclopedia of statistics in behavioral science, Hoboken: John Wiley & Sons, Ltd, 2005."},{"key":"2023033111232997585_j_cclm-2019-0655_ref_023","doi-asserted-by":"crossref","unstructured":"Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Hoier-Madsen M, Wijk A, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998;37:39\u201345.","DOI":"10.1093\/rheumatology\/37.1.39"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_024","doi-asserted-by":"crossref","unstructured":"Han E, Jo SJ, Lee H, Choi AR, Lim J, Jung ES, et al. Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis. Clin Chim Acta 2017;464:113\u20137.","DOI":"10.1016\/j.cca.2016.11.021"},{"key":"2023033111232997585_j_cclm-2019-0655_ref_025","doi-asserted-by":"crossref","unstructured":"Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431\u20137.","DOI":"10.1111\/j.1572-0241.2003.07257.x"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/cclm\/58\/3\/article-p416.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0655\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0655\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:42:45Z","timestamp":1680259365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0655\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,11,12]]},"published-print":{"date-parts":[[2020,2,25]]}},"alternative-id":["10.1515\/cclm-2019-0655"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2019-0655","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,12]]}}}